This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

by user


For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there’s another grouping that has kept right up with them, and with a lot lower risk.

It’s called GRANOLAS, a term coined by Goldman Sachs during 2020 to refer to the largest European companies at that time: GSK
GSK,
+0.22%
,
Roche
ROG,
+0.87%
,
ASML
ASML,
+2.89%
,
Nestlé
NESN,
+0.73%
,
Novartis
NOVN,
-1.01%
,
Novo Nordisk
NVO,
+2.37%
,
L’Oréal
OR,
+2.13%
,
LVMH
MC,
+0.35%
,
AstraZeneca
AZN,
-1.98%
,
SAP
SAP,
+0.22%

and Sanofi
SNY,
-0.13%
.

This chart shows, in total return terms since January 2021, that the GRANOLAS grouping has kept right up with the Magnificent Seven of Amazon.com
AMZN,
+2.71%
,
Apple
AAPL,
+0.41%
,
Alphabet
GOOGL,
+2.12%
,
Meta Platforms
META,
-0.40%
,
Microsoft
MSFT,
+1.56%
,
Nvidia
NVDA,
+3.58%

and Tesla
TSLA,
+2.12%
,
with a 63% return, and volatility since 2018 that is on average twice was low.

They’re a lot cheaper than the Mag 7, trading at 20 times earnings versus 30, though the GRANOLAS are more expensive to the broader European market.

This grouping has had a strong fourth quarter reporting season, led by Novo Nordisk’s success with weight-loss drugs, and ASML’s surge of microchip-equipment making machines, although L’Oréal disappointed in part due to its struggles in China.

“In our view, the reason why this group of stocks trades at a premium to the market is that they offer strong (and predictable) growth,” said strategists led by Guillaume Jaisson.

They say the time to own the GRANOLAS is when global GDP growth is below 3%, which is what the bank expects over the next five years.

Perhaps surprisingly in a world stuffed with exchange-traded funds, Goldman has not created a fund to trade on its moniker, meaning investors who want exposure to the theme would have to buy each stock individually.



Source link

Related Posts

Leave a Review

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy